Expansion will focus on supporting high growth industries in India, including biotechnology, process safety, and pharmaceutical industries
Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin
“We look forward to advancing our launch plans for this important product, and we believe this withdrawal re-affirms our confidence in ultimate success,” stated Scott Tarriff, Pre and CEO Eagle Pharmaceuticals.
"AR882 has the potential to address an unmet treatment need for patients with chronic gout, and we are excited to begin this Phase 2b clinical study," said Litain Yeh, PhD, President and CEO of Arthrosi Therapeutics.
Agendia Spotlight Poster at SABCS 2021 Confirms Utility of BluePrint® as Biomarker Subtyping Test to Guide Neoadjuvant Chemotherapy Decisions
The spotlight presentation, resulting from a research collaboration between Agendia and the Netherlands Cancer Institute and titled Effect of pertuzumab plus neoadjuvant trastuzumab-based chemotherapy in early-stage HER2-positive breast cancer according to BluePrint molecularly defined breast cancer subtypes [PD15-07], evaluates the BluePrint 80-gene molecular subtyping test for predicting response to neoadjuvant trastuzumab-based chemotherapy with or without pertuzumab in a large nationwide cohort of patients from the TRAIN2 study (NCT01996267) and the Netherlands Cancer Registry.
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18
The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects such as the stimulation of insulin secretion and the inhibition of glucagon, when blood glucose is high.
“We are pleased to receive this important designation from the Agency and look forward to partnering with them,” said Joe C. Loy, CEO of Zetagen Therapeutics.
"At IFM, we believe innate immune biology offers a multitude of genetically-validated, clinically-relevant targets and pathways across several therapeutic areas," said H. Martin Seidel, Ph.D., CEO of IFM Therapeutics.
European Commission Approves LENVIMA Plus KEYTRUDA for Patients With Certain Types of Endometrial Carcinoma
This marks the first combination of tyrosine kinase inhibitor with immunotherapy approved in Europe for these patients with advanced or recurrent endometrial carcinoma.
Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy
Dr. Avinash Desai, Actinium's Chief Medical Officer, said, "This novel combination has produced promising data with high rates of remission and MRD negativity with an acceptable safety profile thus far.
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
“We continue to gain momentum with the U.S. ZYNLONTA launch, and we are pleased to be making progress in Europe with the submission and validation of our MAA,” said Chris Martin, Ph.D., Chief Executive Officer of ADC Therapeutics.
X WPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain
Avance Clinical CEO Yvonne Lungershausen congratulated XWPharma saying: “Avance Clinical has an international reputation for expediting clinical trials in Australia which has an exceptionally supportive regulatory environment for biotechs”.